CONSHOHOCKEN, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated ...
Two oral presentations to highlight biomarker, imaging and quality-of-life data from the open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 trial of Rezdiffra Poster of ...
The MarketWatch News Department was not involved in the creation of this content. Oral GPR119 Agonist Demonstrated Clinically Meaningful Reductions in HbA1c, Improvements in Liver Inflammation and ...
Please provide your email address to receive an email when new articles are posted on . Metabolic dysfunction-associated steatohepatitis is significantly more common in patients with type 2 diabetes, ...
Hosted on MSN
Madrigal Pharmaceuticals Reports Promising Two-Year Data for Rezdiffra in MASH Cirrhosis
CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has announced two-year results from the open-label arm of its Phase 3 MAESTRO-NAFLD-1 trial, showcasing the potential of Rezdiffra for ...
Denifanstat’s Phase 2b MASH trial met both FDA-aligned primary endpoints with statistical significance—showing fibrosis improvement without worsening MASH and MASH resolution without worsening ...
In phase 2 trials involving patients with stage 2 or 3 fibrosis caused by metabolic dysfunction–associated steatohepatitis (MASH), efruxifermin, a bivalent fibroblast growth factor 21 (FGF21) analogue ...
Gene expression analysis from the STAM mouse model attributes Thykamine™ with dose-dependent anti-MASH, anti-inflammatory and anti-fibrosis molecular effects in liver QUÉBEC, Feb. 12, 2026 /PRNewswire ...
Oral GPR119 Agonist Demonstrated Clinically Meaningful Reductions in HbA1c, Improvements in Liver Inflammation and Fibrosis, and Favorable Changes in Plasma Lipidomic Profiles "The encouraging ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results